Retrospective Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Mar 6, 2022; 10(7): 2106-2114
Published online Mar 6, 2022. doi: 10.12998/wjcc.v10.i7.2106
Table 3 Single factor analysis of major adverse cardiovascular events occurrence
Data
MACE group (n = 29)
Non-MACE group (n = 135)
t/χ2
P value
Age (yr)63.9 ± 7.765.0 ± 8.1-0.6690.504
BMI (kg/m2)24.1 ± 2.023.8 ± 2.40.6280.531
HR (times/min)91.6 ± 8.293.0 ± 7.6-0.8880.376
Number of implanted stents1.85 ± 0.451.98 ± 0.50-1.2920.198
Gender1.0020.317
Male18 (62.07)70 (51.85)
Female11 (37.93)65 (48.15)
Diabetes4.3140.038
Yes9 (31.03)20 (14.81)
No20 (68.97)115 (85.19)
Hypertension3.7580.053
Yes13 (44.83)36 (26.67)
No16 (55.17)99 (73.33)
Hyperlipidemia1.8510.174
Yes18 (62.07)65 (48.15)
No11 (37.93)70 (51.85)
Smoking1.8510.174
Yes11 (37.93)34 (25.19)
No18 (62.07)101 (74.81)
Infarct related blood vessel5.7290.126
Anterior descending branch16 (55.17)43 (31.85)
Circumflex4 (13.79)29 (21.48)
Left main stem2 (6.9)11 (8.15)
Right coronary artery7 (24.14)52 (38.52)
Killp rating 0.8050.370
1-2 degree22 (75.86)112 (82.96)
3-4 degree7 (24.14)23 (17.04)
Use ACEI1.2770.258
Yes18 (62.07)98 (72.59)
No11 (37.93)37 (27.41)
Use beta blockers0.8180.366
Yes21 (72.41)108 (80.00)
No8 (27.59)27 (20.00)
TIMI grading6.0460.014
3 degree13 (44.83)93 (68.89)
< 3 degree16 (55.17)42 (31.11)
TMPG grading3.8610.049
3 degree13 (44.83)87 (64.44)
< 3 degree16 (55.17)48 (35.56)
Timing of stent implantation6.6830.010
Immediately19 (65.52)53 (39.26)
Extension10 (34.48)82 (60.74)
Intraoperative use of tirofiban4.5990.032
Yes17 (58.62)105 (77.78)
No12 (41.38)30 (22.22)
CK-MB peak (U/L)226.4 ± 44.1218.0 ± 40.80.9920.323
WBC (109/L)12.63 ± 2.0111.18 ± 1.803.8540.000
N (109/L)9.80 ± 1.1415.13 ± 0.63-35.0220.000
RDW13.54 ± 2.0812.61 ± 1.862.3920.018
UA (μmol/L)368.1 ± 42.2340.7 ± 38.53.4180.001
hs-CRP (mg/L)10.58 ± 2.818.62 ± 2.513.7340.000